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osting by EAbstract A series of 2-[2-(substituted benzylidene) hydrazinyl]-4-(4-methoxyphenyl)-6-oxo-1,
6-dihydro-pyrimidine-5-carbonitrile (3–16) were synthesized by reﬂuxing 2-hydrazino-4-(4-meth-
oxy-phenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (2) with different substituted aromatic
aldehydes in glacial acetic acid and absolute alcohol mixture (8:2). The compounds were evaluated
for their anticonvulsant and neurotoxicity effect. In MES test compounds 2-[2-(4-bromo-benzyli-
dene)-hydrazinyl]-4-(4-methoxyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (5), 2-[2-(4-
hydroxy-benzylidene)-hydrazinyl]-4-(4-methoxyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile
(9), and 2-[2-(3-ﬂuoro-benzylidene)-hydrazinyl]-4-(4-methoxyphenyl)-6-oxo-1,6-dihydro-pyrimi-
dine-5-carbonitrile (16) were found to be highly active at a dose level of 30 mgkg1 at 0.5 h time
interval, indicating their ability to prevent seizure spread at a relatively low dose.
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lsevier1. Introduction
Seizure, a clinical expression of abnormal neuron ﬁrings within
the brain, occurs with or without loss of consciousness leads to
epilepsy. Approximately 0.4–1% of patients worldwide suffers
from epilepsy (Aggarwal et al., 2009). All the present antiepi-
leptic drugs have dose-related toxicity and idiosyncratic side
effects (Brodie, 1990).
In recent years Schiff’s bases, have gained much attention
due to its wide spectrum of biological activities like anticon-
vulsant (Ragavendran et al., 2007; Cakir et al., 2001), antide-
pressant (Ergenc and Gunay, 1998), anti-inﬂammatory
(Duarte et al., 2007), antimalarial (Bernardino et al., 2006),
antimycobacterial (Imramovsky et al., 2007), etc. Nifuroxaz-
ide (Fig. 1), an intestinal antiseptic (Rollas et al., 2002) is a
Schiff’s base.
Cakir et al. (2001) have synthesized ﬁfteen Schiff’s bases and
out of them N0-(4-ﬂuoro-benzylidene)-2-(2-oxobenzo[d]oxazol-3
ON N
H
H
O
NO2
OH
Figure 1 Nifuroxazide.
150 M. Shaquiquzzaman et al.(2H)-yl) aceto-hydrazide (Fig. 2) was found to be a very active
anticonvulsant.
Owing to the versatility of Schiff’s bases we have synthesized
fourteen new 2-[2-(substituted benzylidene) hydrazinyl]-4-(4-
methoxyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile
using the modiﬁcation of one-pot Biginelli reaction (Kappe,
1993) and evaluated them for their anticonvulsant effect using
MES method (Loscher et al., 1991). They were also tested for
their neurotoxicity effect by rotorod test (Clark et al., 1984).
2. Materials and methods
2.1. General
Chemicals were purchased from Merck and Sigma–Aldrich as
‘synthesis grade’ and used without further puriﬁcation. Melt-
ing points were determined by open tube capillary method
and are uncorrected using Analab Scientiﬁc Instrument. Purity
of the compounds was checked by thin layer chromatography
(TLC) on silica gel G Plates (Merck No. 5544) using toluene–
ethyl acetate–formic acid (5:4:1) as solvent system and the
spots were located either under ultra violet light or through
the exposure to iodine vapors.
The IR spectra were measured using a Bruker alpha-T spec-
trophotometer. 1H NMR spectra were recorded on Bruker
Avance-400 MHz in DMSO-d6 with tetramethylsilane (TMS)
as an internal standard; chemical shifts (d) are reported in
parts per million (ppm) downﬁeld from TMS. Mass spectra
were recorded on a Jeol JMS-D 300 instrument ﬁtted with a
JMS 2000 data system at 70 eV. Spectral data are consistent
with assigned structures. Elemental analyses were performed
on a Perkin-Elmer model 240 analyzer (C, H, N) and found
within the range of ±0.4% of theoretical values.
2.2. Chemistry
2.2.1. General procedure for the synthesis of 2-mercapto-4-(4-
methoxy-phenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (1)
Anisaldehyde (1 mmol), ethyl cyanoacetate (1 mmol) and thio-
urea (1 mmol) were dissolved in absolute alcohol. Potassium
carbonate (3 mmol) was added to this reaction mixture and
reﬂuxed for 2 h. The solvent was concentrated and poured intoO
N
C
H2 N
H
N
C
H
F
O
O
Figure 2 N0-(4-Fluoro-benzylidene)-2-(2-oxobenzo[d]oxazol-
3(2H)-yl) aceto-hydrazide.ice cold water with stirring. The solution was neutralized with
glacial acetic acid, which causes the separation of solid which
was ﬁltered, washed with water and recrystallized from meth-
anol. Yield: 90%; mp 139–40 C; Rf 0.6; IR (cm1): 3245 (–NH
of amide), 3215 (–NH), 2225 (C„N), 1674 (C‚O), 1165
(C‚S); 1H NMR (d, ppm): 3.83 (s, 3H, OCH3), 6.87 (d, 2H,
J= 8.4 Hz, H-3,5, Phenyl), 7.86 (d, 2H, J= 8.4 Hz, H-2,6,
Phenyl), 9.60 (s, 1H, NH), 12.06 (br s, 1H, NH–C‚O).
2.2.2. General procedure for the synthesis of 2-hydrazino-4-(4-
methoxy-phenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile
(2)
To a solution of compound 1 (1 mmol) in absolute ethanol,
hydrazine hydrate (99%; 4 mmol) was added and reﬂuxed
for 1 h. The reaction mixture was allowed to cool which re-
sulted in the separation of solid. The precipitated product
was ﬁltered and washed with water. It was recrystallized with
ethanol. Yield: 82%; mp 179–80 C; Rf 0.2; IR (cm1): 3285
(–NH of amide), 3218 (–NHNH2), 2210 (C„N), 1680
(C‚O), 1065 (C–O–C); 1H NMR (d, ppm): 3.84 (s, 3H,
OCH3), 3.97 (br s, 3H, NHNH2), 6.93 (d, 2H, J= 8.4 Hz,
H-3,5, phenyl), 7.77 (d, 2H, J= 8.4 Hz, H-2,6, phenyl),
11.71 (br s, 1H, NH–C‚O).
2.2.3. General procedure for the synthesis of 2-[2-(substituted
benzylidene) hydrazinyl]-4-(4-methoxyphenyl)-6-oxo-1,6-dihydro-
pyrimidine-5-carbonitrile (3–16)
Compound 2 (1 mmol) was dissolved in a mixture of glacial
acetic acid and absolute alcohol (8:2). To this solution, abso-
lute alcoholic solution of substituted aromatic aldehydes
(1.1 mmol) was added and reﬂuxed for 2–3 h. Solvent was con-
centrated to half of its volume, poured into ice water. The pre-
cipitate obtained was ﬁltered, washed with water and
recrystallized from methanol.
2.2.3.1. 2-(2-Benzylidene-hydrazinyl)-4-(4-methoxyphenyl)-6-
oxo-1,6-dihydro-pyrimidine-5-carbonitrile (3). Yield: 65%, mp
205–06 C, Rf: 0.4; IR (cm1): 3270 (–NH of amide), 3210
(–NH), 2215 (C„N), 1676 (C‚O), 1609 (C‚N), 1071 (C–
O–C); 1H NMR (d, ppm): 3.86 (s, 3H, OCH3), 6.91 (d, 2H,
J= 8.8 Hz, H-3,5, phenyl), 7.13–7.32 (m, 5H, ArH, arylidene
ring), 7.83 (d, 2H, J= 8.8 Hz, H-2,6, phenyl), 8.01 (s, 1H,
N‚CH), 9.34 (s, 1H, NH–N‚), 12.03 (br s, 1H, NH–
C‚O); Mass (m/z): 344(M+). Anal. Calcd. for C19H15N5O2:
C, 66.08; H, 4.38; N, 20.28. Found: C, 66.84; H, 4.37; N, 20.26.
2.2.3.2. 2-[2-(2-Chloro-benzylidene)-hydrazinyl]-4-(4-methoxy
phenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (4). Yield:
84%; mp 203–04 C; Rf: 0.4; IR (cm1): 3296 (–NH of amide),
3218 (–NH), 2214 (C„N), 1670 (C‚O), 1614 (C‚N), 1102
(Ar-Cl); 1H NMR (d, ppm): 3.85 (s, 3H, OCH3), 6.97 (d, 2H,
J= 8.0 Hz, H-3,5, phenyl), 7.32–7.56 (m, 4H, H-30,40,50,60,
arylidene ring), 7.80 (d, 2H, J= 8.0 Hz, H-2,6, phenyl), 8.04
(s, 1H, N‚CH), 11.65 (br s, 1H, NH–N‚), 12.06 (br s, 1H,
NH–C‚O); Mass (m/z): 379(M+), 381 (M+2). Anal. Calcd.
for C19H14ClN5O2 : C, 60.09; H, 3.72; N, 9.33. Found: C,
60.28; H, 3.71; N, 9.32.
2.2.3.3. 2-[2-(4-Bromo-benzylidene)-hydrazinyl]-4-(4-methoxy
phenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (5). Yield:
75%; mp 235–36 C; Rf: 0.5; IR (cm1): 3348 (–NH of amide),
3272 (–NH), 2216 (C„N), 1668 (C‚O), 1618 (C‚N), 1084
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J= 8.0 Hz, H-3,5, phenyl), 7.41 (d, 2H, J= 7.6 Hz, H-20,60,
arylidene ring), 7.64 (d, 2H, J= 7.6 Hz, H-30,50, arylidene
ring), 7.87 (d, 2H, J= 8.0 Hz, H-2,6, phenyl), 8.10 (s, 1H,
N‚CH), 11.83 (br s, 1H, NH–N‚), 12.25 (br s, 1H, NH–
C‚O); Mass (m/z): 423(M+). Anal. Calcd. for
C19H14BrN5O2: C, 53.79; H, 3.33; N, 16.51. Found: C,
53.94; H, 3.34; N, 16.49.
2.2.3.4. 2-[2-(3-Bromo-benzylidene)-hydrazinyl]-4-(4-methox
yphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (6).
Yield: 64%; mp 241–42 C; Rf: 0.5; IR (cm1): 3368 (–NH of
amide), 3313 (–NH), 2219 (C„N), 1676 (C‚O), 1620
(C‚N), 1078 (Ar-Br); 1H NMR (d, ppm): 3.91 (s, 3H,
OCH3), 6.93 (d, 2H, J= 8.8 Hz, H-3,5, phenyl), 7.33 (t, 1H,
J= 7.6 Hz, H-50, arylidene ring), 7.48 (d, 1H, J= 7.6 Hz,
H-60, arylidene ring), 7.52 (d, 1H, J= 7.6 Hz, H-40, arylidene
ring), 7.81 (s, 1H, H-20, arylidene ring), 7.90 (d, 2H,
J= 8.8 Hz, H-2,6, phenyl), 8.11 (s, 1H, N‚CH), 11.85 (br
s, 1H, NH–N‚), 12.21 (br s, 1H, NH–C‚O); Mass (m/z):
423(M+). Anal. Calcd. for C19H14BrN5O2: C, 53.79; H, 3.33;
N, 16.51. Found: C, 53.84; H, 3.34; N, 16.50.
2.2.3.5. 2-[2-(2,4-Dichloro-benzylidene)-hydrazinyl]-4-(4-meth
oxyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (7).
Yield: 80%; mp 217–18 C; Rf: 0.5; IR (cm1): 3314 (–NH of
amide), 3230 (–NH), 2220 (C„N), 1665 (C‚O), 1614
(C‚N), 1112 (Ar-Cl); 1H NMR (d, ppm): 3.87 (s, 3H,
OCH3), 7.01 (d, 2H, J= 8.4 Hz, H-3,5, phenyl), 7.34 (d, 1H,
J= 8.8 Hz, H-50, arylidene ring), 7.48 (d, 1H, J= 8.8 Hz,
H-60, arylidene ring), 7.75 (s, 1H, H-30, arylidene ring), 7.86
(d, 2H, J= 8.4 Hz, H-2,6, phenyl), 8.06 (s, 1H, N‚CH),
11.54 (br s, 1H, NH–N‚), 12.12 (br s, 1H, NH–C‚O); Mass
(m/z): 413(M+), 415(M+2). Anal. Calcd. for C19H13Cl2N5O2:
C, 55.09; H, 3.16; N, 16.91. Found: C, 54.79; H, 3.17; N, 16.92.2.2.3.6. 2-[2-(2,6-Dichloro-benzylidene)-hydrazinyl]-4-(4-meth
oxyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (8).
Yield: 80%; mp 211–12 C; Rf: 0.4; IR (cm1): 3311 (–NH of
amide), 3265 (–NH), 2209 (C„N), 1672 (C‚O), 1613
(C‚N), 1096 (Ar-Cl); 1H NMR (d, ppm): 3.80 (s, 3H,
OCH3), 6.98 (d, 2H, J= 8.4 Hz, H-3,5, phenyl), 7.43 (t, 1H,
J= 8.8 Hz, H-40, arylidene ring), 7.67 (d, 2H, J= 8.8 Hz,
H-30,50, arylidene ring), 7.88 (d, 2H, J= 8.4 Hz, H-2,6, phe-
nyl), 8.09 (s, 1H, N‚CH), 11.83 (br s, 1H, NH–N‚), 12.17
(br s, 1H, NH–C‚O); Mass (m/z): 413(M+), 415(M+2).
Anal. Calcd. for C19H13Cl2N5O2: C, 55.09; H, 3.16; N,
16.91. Found: C, 54.82; H, 3.17; N, 16.93.2.2.3.7. 2-[2-(4-Hydroxy-benzylidene)-hydrazinyl]-4-(4-metho
xyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (9).
Yield: 80%; mp 219–20 C; Rf: 0.5; IR (cm1): 3467 (Ar-
OH), 3315 (–NH of amide), 3242 (–NH), 2216 (C„N), 1661
(C‚O), 1620 (C‚N); 1H NMR (d, ppm): 3.84 (s, 3H,
OCH3), 6.81 (d, 2H, J= 8.8 Hz, H-3
0,50, arylidene ring),
6.95 (d, 2H, J= 8.0 Hz, H-3,5, phenyl), 7.52 (d, 2H,
J= 8.8 Hz, H-20,60, arylidene ring), 7.84 (d, 2H, J= 8.0 Hz,
H-2,6, phenyl), 8.08 (s, 1H, N‚CH), 10.38 (br s, 1H, OH),
11.36 (br s, 1H, NH–N‚), 12.01 (br s, 1H, NH–C‚O); Mass
(m/z): 360(M+). Anal. Calcd. for C19H15N5O3: C, 63.15; H,
4.18; N, 19.38. Found: C, 63.27; H, 4.19; N, 19.36.2.2.3.8. 2-[2-(3-Nitro-benzylidene)-hydrazinyl]-4-(4-methoxy-
phenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (10).
Yield: 80%; mp 191–92 C; Rf: 0.6; IR (cm1): 3354 (–NH of
amide), 3292 (–NH), 2226 (C„N), 1669 (C‚O), 1612
(C‚N), 1524, 1346 (NO2) ;
1H NMR (d, ppm): 3.90 (s, 3H,
OCH3), 7.02 (d, 2H, J= 8.4 Hz, H-3,5, phenyl), 7.67 (dd,
1H, J= 8.0 Hz and7.6 Hz, H-50, arylidene ring), 7.85 (d, 2H,
J= 8.4 Hz, H-2,6, phenyl), 8.04 (d, 1H, J= 7.6 Hz, H-60, ary-
lidene ring), 8.13 (s, 1H, N‚CH), 8.27 (d, 1H, J= 8.0 Hz, H-
40, arylidene ring), 8.46 (s, 1H, H-20, arylidene ring), 11.91 (br
s, 1H, NH–N‚), 12.34 (br s, 1H, NH–C‚O); Mass (m/z):
389(M+). Anal. Calcd. for C19H14N6O4: C, 58.46; H, 3.61;
N, 21.53. Found: C, 58.74; H, 3.60; N, 21.57.
2.2.3.9. 2-[2-(3,4-Dimethoxy-benzylidene)-hydrazinyl]-4-(4-
methoxyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile
(11). Yield: 65%; mp 264–65 C; Rf: 0.6; IR (cm1): 3365
(–NH of amide), 3318 (–NH), 2219 (C„N), 1678 (C‚O),
1611 (C‚N), 1090 (C–O–C); 1H NMR (d, ppm): 3.86 (s,
3H, OCH3), 3.88 (s, 6H, 2xOCH3), 6.91 (d, 2H, J= 8.6 Hz,
H-3,5, phenyl), 7.04 (d, 1H, J= 8.8 Hz, H-50, arylidene ring),
7.48 (d, 1H, J= 8.8 Hz, H-60, arylidene ring), 7.63 (s, 1H, H-
20, arylidene ring), 7.93 (d, 2H, J= 8.6 Hz, H-2,6, phenyl),
8.14 (s, 1H, N‚CH), 11.74 (br s, 1H, NH–N‚), 12.06 (br s,
1H, NH–C‚O); Mass (m/z): 404(M+). Anal. Calcd. for
C21H19N5O4: C, 62.22; H, 4.72; N, 17.27. Found: C, 62.38;
H, 4.71; N, 17.26.
2.2.3.10. 2-[2-(3,4,5-Trimethoxy-benzylidene)-hydrazinyl]-4-
(4-methoxyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile
(12). Yield: 70%; mp 244–45 C; Rf: 0.6; IR (cm1): 3324
(–NH of amide), 3242 (–NH), 2214 (C„N), 1668 (C‚O),
1615 (C‚N), 1068 (C–O–C); 1H NMR (d, ppm): 3.83 (s,
3H, OCH3), 3.88 (s, 9H, 3 · OCH3), 6.83 (s, 2H, H-20,60, ary-
lidene ring), 6.92 (d, 2H, J= 8.6 Hz, H-3,5, phenyl), 7.93 (d,
2H, J= 8.6 Hz, H-2,6, phenyl), 8.03 (s, 1H, N‚CH), 11.92
(br s, 1H, NH–N‚), 12.11 (br s, 1H, NH–C‚O); Mass (m/
z): 434(M+). Anal. Calcd. for C22H21N5O5: C, 60.68; H,
4.86; N, 16.08. Found: C, 60.58; H, 4.85; N, 16.09.
2.2.3.11. 2-[2-(4-Hydroxy-3-methoxy-benzylidene)-hydrazinyl
]-4-(4-methoxyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbo-
nitrile (13). Yield: 78%; mp 227–28 C; Rf: 0.5; IR (cm1):
3445 (Ar-OH), 3306 (–NH of amide), 3215 (–NH), 2218
(C„N), 1672 (C‚O), 1624 (C‚N), 1072 (C–O–C); 1H
NMR (d, ppm): 3.88 (s, 3H, OCH3), 3.95 (s, 3H, OCH3),
6.82 (d, 1H, J= 8.4 Hz, H-50, arylidene ring), 7.00 (d, 2H,
J= 8.4 Hz, H-3,5, phenyl), 7.14 (d, 1H, J= 8.4 Hz, H-60, ary-
lidene ring), 7.92 (d, 2H, J= 8.4 Hz, H-2,6, phenyl), 7.95 (s,
1H, H-20, arylidene ring), 8.07 (s, 1H, N‚CH), 9.37 (s, 1H,
OH), 11.73 (br s, 1H, NH–N‚), 12.24 (br s, 1H, NH–
C‚O); Mass (m/z): 390(M+). Anal. Calcd. for C20H17N5O4:
C, 61.38; H, 4.38; N, 17.89. Found: C, 61.17; H, 4.39; N, 17.91.
2.2.3.12. 2-[2-(4-Dimethylamino-benzylidene)-hydrazinyl]-4-
(4-methoxyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile
(14). Yield: 75%; mp 215–16 C; Rf: 0.5; IR (cm1): 3318
(–NH of amide), 3258 (–NH), 2211 (C„N), 1672 (C‚O),
1618 (C‚N); 1H NMR (d, ppm): 2.32 (s, 6H, 2xCH3), 3.88
(s, 3H, OCH3), 6.86 (d, 2H, J= 8.8 Hz, H-3
0,50, arylidene
ring), 6.96 (d, 2H, J= 8.4 Hz, H-3,5, phenyl), 7.84 (d, 2H,
J= 8.4 Hz, H-2,6, phenyl), 7.92 (d, 2H, J= 8.8 Hz, H-20,60,
Table 1 Anticonvulsant activity and minimal motar impairment of synthesized compounds 3–16.
(3-16)
R
N
NH
NC
O
N
H
N
MeO
Compound R MES screen after injection (h)a Neurotoxicity screen after injection (h)a LogPb
After 0.5 h After 4 h After 0.5 h After 4 h
3 H 100 300 (–) (–) 2.09
4 2-Cl 100 300 (–) 300 2.39
5 4-Br 30 100 300 300 2.45
6 3-Br 100 (–) 300 300 2.35
7 2,4-Cl2 300 300 x x 2.68
8 2,6-Cl2 100 300 (–) 300 2.62
9 4-OH 30 100 (–) (–) 1.27
10 3-NO2 100 300 300 (–) 1.18
11 3,4-(OCH3)2 100 300 300 (–) 1.89
12 3,4,5-(OCH3)3 100 300 (–) (–) 1.67
13 3-OCH3-4-OH 100 300 (–) (–) 1.51
14 4-N(CH3)2 300 300 300 (–) 2.32
15 2,4,6-(CH3)3 (–) 300 x x 2.71
16 3-F 30 100 (–) (–) 2.13
Phenytoinc – 30 30 100 100 –
a Doses of 30, 100, 300 mgkg1 were administered i.p. Test compounds were suspended in 0.5% methylcellulose/water mixture or in polyethylene
glycol (PEG). Figures in the table indicate the minimum dose with bioactivity demonstrated in half or more of the mice. The dash (–) indicates the
absence of activity at maximum dose administered (300 mgkg1). The ‘‘x’’ indicates not tested.
b LogP was calculated using ACD lab version 8.0.
c Data from references Siddiqui et al. (2010, 2009).
152 M. Shaquiquzzaman et al.arylidene ring), 8.01 (s, 1H, N‚CH), 11.86 (br s, 1H, NH–
N‚), 12.08 (br s, 1H, NH–C‚O); Mass (m/z): 387(M+).
Anal. Calcd. for C21H20N6O2: C, 64.94; H, 5.19; N, 21.64.
Found: C, 65.12; H, 5.18; N, 21.62.
2.2.3.13. 2-[2-(2,4,6-Trimethyl-benzylidene)-hydrazinyl]-4-(4-
methoxyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile
(15). Yield: 65%; mp 225–26 C; Rf: 0.4; IR (cm1): 3336
(–NH of amide), 3281 (–NH), 2228 (C„N), 1676 (C‚O),
1624 (C‚N); 1H NMR (d, ppm): 2.28 (s, 3H, CH3), 2.54 (s,
6H, 2 · CH3), 3.86 (s, 3H, OCH3), 6.81 (s, 2H, H-30,50, arylid-
ene ring), 6.93 (d, 2H, J= 8.4 Hz, H-3,5, phenyl), 7.88 (d, 2H,
J= 8.4 Hz, H-2,6, phenyl), 8.04 (s, 1H, N‚CH), 11.69 (br s,
1H, NH–N‚), 12.04 (br s, 1H, NH–C‚O); Mass (m/z):
396(M+), 386(M+2). Anal. Calcd. for C22H21N5O2: C,
68.20; H, 5.46; N, 18.08. Found: C, 68.33; H, 5.45; N, 18.09.
2.2.3.14. 2-[2-(3-Fluoro-benzylidene)-hydrazinyl]-4-(4-methox
yphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (16).
Yield: 72%; mp 255–56 C; Rf: 0.5; IR (cm1): 3346 (–NH of
amide), 3308 (–NH), 2224 (C„N), 1669 (C‚O), 1617
(C‚N), 1142 (Ar-F); 1H NMR (d, ppm): 3.93 (s, 3H,
OCH3), 6.88 (d, 2H, J= 8.8 Hz, H-3,5, phenyl), 7.31–7.72
(m, 4H, H-20,40,50,60, arylidene ring), 7.94 (d, 2H, J= 8.8 Hz,H-2,6, phenyl), 8.16 (s, 1H, N‚CH), 11.93 (br s, 1H, NH–
N‚), 12.26 (br s, 1H, NH–C‚O); Mass (m/z): 370(M+).
Anal. Calcd. for C21H17N5O2: C, 67.91; H, 4.61; N, 18.86.
Found: C, 67.74; H, 4.60; N, 18.87.
2.3. Pharmacology
Swiss albino mice used in the present study were housed and
kept in accordance with the Hamdard University animal care
unit, which applies the guidelines and rules laid down by the
Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA), Ministry of Social Justice
andEmpowerment, Government of India. Albinomice of either
sex weighing 22–25 g, were used. The animals were housed in
groups of six and acclimatized to room conditions for at least
2 days before the experiments. Food andwater were freely avail-
able up to the time of experiments except during the short time
they were removed from the cages for testing.
2.3.1. Anticonvulsant activity
The synthesized compounds were evaluated for their anticon-
vulsant activity using maximal electroshock (MES) method
(Loscher et al., 1991) with phenytoin as standard drug. The
convulsion was measured using Ugo Basile Convulsiometer.
MeO CHO + C
H2
OC2H5NC
O
+ NH2 NH2
S
(i)
N
NH
NC
O
SH
MeO
(ii)
N
NH
NC
O
N
H
NH2
MeO
(iii)
(1)
(2) (3-16)
R
N
NH
NC
O
N
H
N
MeO
MeO
N
H
NH
NC
O
S
Scheme 1 Reagents and conditions: (i) K2CO3, Abs. alcohol, reﬂux; (ii) hydrazine hydrate, Abs. alcohol, reﬂux; (iii) aromatic aldehyde,
Glacial acetic acid, reﬂux.
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Mice were stimulated through corneal electrodes to 50 mA cur-
rent at a pulse of 60 Hz applied for 0.25 s. Animals were pre-
viously given the test drug i.p. Abolition of the hind limb
tonic extension spasm was recorded as the anticonvulsant
activity. In preliminary screening, each compound was admin-
istered through an i.p. injection at three dose levels (30, 100
and 300 mgkg1 body mass) and the anticonvulsant activity
was assessed after 0.5 and 4 h intervals of administration.
2.3.2. Neurotoxicity
The synthesized drugs interference with motor coordination
was checked by the rotorod test (Clark et al., 1984). In that test
mice were trained to stay on the knurled plastic rod having
diameter of 3.2 cm. Normal mice could maintain equilibrium
on the rotating rod for longer period of time. The neurotox-
icity was indicated by inability of the animal to maintain equi-
librium on the rod for at least one minute in each of the three
trials and it is expressed as the number of animals exhibiting
toxicity or the number of animals tested.3. Results and discussion
Fourteen new compounds (3–16) were synthesized as outlined in
Scheme 1. The title compounds 2-[2-(substituted benzylidene)
hydrazinyl]-4-(4-methoxy-phenyl)-6-oxo-1,6-dihydro-pyrimidine-
5-carbonitrile derivatives, a Schiff’s base, were synthesized by
reﬂuxing 2-hydrazino-4-(4-methoxy-phenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (2) with different substituted aromatic
aldehydes in glacial acetic acid and absolute alcohol mixture
(8:2). The required intermediate compound 2was synthesized from
2-mercapto-4-(4-methoxy-phenyl)-6-oxo-1,6-dihydro-pyrimidine-
5-carbonitrile 1uponnucleophilic attack by the hydrazine hydrate.
The compound 1was synthesized bymodiﬁed Biginelle condensa-
tion method using anisaldehyde, ethyl cyanoacetate and thiourea
in the presence of potassium carbonate. In general, the IR spectral
data of all the compounds showed characteristic peaks around
3346 cm1 for –NH of amide group, 2224 cm1 for C„N and
1669 cm1 forC‚O indicating the formation of cyanopyrimidine.
Similarly, peak around 1617 cm1 indicates the formation of
Schiff’s base.
In 1H NMR spectral data, all the compounds showed char-
acteristic peak at appropriate d-values. Presence of a singlet
around d 8.05 indicates the formation of benzylidene i.e.
Schiff’s base. Similarly, broad singlet around d 12.11 indicates
the formation of cyano-pyrimidine ring. The structure of the
compounds was further supported by mass spectral data.
The synthesized compounds gave M+ peak in reasonable
intensities. The molecular ion or other related ions produced
the appropriate isotopic abundances due to the presence of
chlorine atom(s).
The synthesized compounds were evaluated for anticonvul-
sant activity along with their neurotoxicity effect and the data
is summarized in Table 1. All the compounds showed encour-
aging anticonvulsant activity.
The results illustrate that 2-[2-(4-bromo-benzylidene)-hydrazi-
nyl)-4-(4-methoxyphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbo-
154 M. Shaquiquzzaman et al.nitrile (5), 2-[2-(4-hydroxy-benzylidene)-hydrazinyl]-4-(4-methox
yphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (9) and
2-[2-(3-ﬂuoro-benzylidene)-hydrazinyl)-4-(4-methoxypheny l)-6-
oxo-1,6-dihydro-pyrimidine-5-carbonitrile (16) were found to be
highly active against the MES test at a dose level of 30 mgkg1
at 0.5 h time interval, indicating their ability to prevent seizure
spread at a relatively low dose.
Compounds 3, 4, 6, 8, 10, 11, 12 and 13 showed moderate
protection at dose level of 100 mgkg1.
The result showed that the majority of synthesized com-
pounds showed encouraging anticonvulsant activity at the
0.5 h interval which indicates rapid onset and shorter duration
of action of synthesized compounds. The result also indicates
that increase in the number of functional groups on arylidene
moiety like in compounds 7, 8, 11, 12, 13 and 15, causes a de-
crease in anticonvulsant activity.
The rotarod test indicates that the most active compounds
(9 and 16) showed the absence of neurotoxicity at maximum
administered dose i.e. 300 mgkg1 as compared to phenytoin
which showed neurotoxicity at a dose level of 100 mgkg1.
Compound 5 which showed good anticonvulsant activity at
a dose level of 30 mgkg1 at 0.5 h was found to be more neu-
rotoxic as compared to compounds 9 and 16. Similarly, com-
pounds 6, 10, 11 and 14 were also found to be less
neurotoxic than reference drug phenytoin. The rest of com-
pounds did not exhibit neurotoxicity.
The lipophilicity (logP) value of the synthesized com-
pounds showed that a compound with minimum value was
found to be highly active. Paradoxically, the least active com-
pound (7 & 15) showed high lipophilicity.4. Conclusion
To sum up, 2-[2-(4-bromo-benzylidene)-hydrazinyl]-4-(4-methox
yphenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carbonitrile (5), 2-[2-(4-
hydroxy-benzylidene)-hydrazinyl)-4-(4-methoxyphenyl)-6-
oxo-1, 6-dihydro-pyrimidine-5-carbonitrile (9) and 2-[2-(3-ﬂu-
oro-benzylidene)-hydrazinyl]-4-(4-methoxyphenyl)-6-oxo-1,6-
dihydro -py rimidine-5-carbonitrile (16) were found to be highly
active against theMES test indicating their ability to prevent sei-
zure. The lipophilicity (logP) value of the synthesized com-pounds showed that a compound with minimum value was
found to be highly active. Paradoxically, the least active com-
pound showed high lipophilicity. Further studies to acquire
more information about the quantitative structure–activity
relationship (QSAR) are in progress in our laboratory.Acknowledgment
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